Venlafaxine besylate is formulated into an extended release tablet in high loading rates by use of a coating that contains ammonio methacrylate copolymer(s).

A modified release tablet of venlafaxine hydrochloride is formed by a core containing a lipophilic matrix and venlafaxine hydroochloride and a water-insoluble permeable coating thereover.

The invention relates to a pharmaceutical composition comprising a solid venlafaxine base and a pharmaceutically acceptable excipient to a process for making a venlafaxine composition which comprises dispersing venlafaxine base in a liquid-phase carrier; and solidifying said liquid phase to form a solid dispersion of venlafaxine and to the use of a pharmaceutical composition as a medicament.

The invention relates to a venlafaxine besylate compound preferably crystalline venlafaxine besylate to a pharmaceutical composition comprising said venlafaxine besylate compound and at least one pharmaceutically acceptable excipient to a method for treating a venlafaxine-treatable disease or condition which comprises administering to a patient in need thereof an effective amount of a venlafaxine besylate compound and to a process for making a venlafaxine besylate composition which comprises: mi...

The invention relates to a pharmaceutical composition comprising a solid venlafaxine base and a pharmaceutically acceptable excipient to a process for making a venlafaxine composition which comprises dispersing venlafaxine base in a liquid-phase carrier; and solidifying said liquid phase to form a solid dispersion of venlafaxine and to the use of a pharmaceutical composition as a medicament.

The invention relates to a venlafaxine besylate compound preferably crystalline venlafaxine besylate to a pharmaceutical composition comprising said venlafaxine besylate compound and at least one pharmaceutically acceptable excipient to a method for treating a venlafaxine-treatable disease or condition which comprises administering to a patient in need thereof an effective amount of a venlafaxine besylate compound and to a process for making a venlafaxine besylate composition which comprises: mi...

The invention relates to a venlafaxine maleate compound to a pharmaceutical composition comprising a venlafaxine maleate compound and a pharmaceutically acceptable excipient to a method for treating a venlafaxine-treatable disease or condition which comprises administering to a patient in need thereof an effective amount of a venlafaxine maleate compound to a low water-soluble venlafaxine salt other than venlafaxine besylate to a pharmaceutical composition comprising a low water-soluble venlafax...

The invention relates to a crystalline racemic venlafaxine base wherein said venlafaxine is in particle form having an average particle size within the range of 0.5 to 200 microns or a bulk density of at least 0.4 mg/ml or a particular XRD pattern to a process for making solid racemic venlafaxine base which comprises precipitating racemic venlafaxine base from a solution of venlafaxine to form crystalline racemic venlafaxine base; wherein said precipitation is carried out in accordance with at l...

The invention relates to a pharmaceutical composition comprising a solid venlafaxine base and a pharmaceutically acceptable excipient to a process for making a venlafaxine composition which comprises dispersing venlafaxine base in a liquid-phase carrier; and solidifying said liquid phase to form a solid dispersion of venlafaxine and to the use of a pharmaceutical composition as a medicament.

The invention relates to a pharmaceutical composition comprising venlafaxine hydrochloride and sodium carboxymethyl cellulosewherein preferably said composition is in the form of a tablet containing a pharmaceutically effective amount of venlafaxine hydrochloride and to a method for treating a venlafaxine-treatable disease or condition which comprises administering to a patient in need thereof an effective amount of the pharmaceutical composition.